Ad is loading...
SLNCF
Price
$5.50
Change
-$0.00 (-0.00%)
Updated
Nov 15 closing price
SOLTF
Price
$8.05
Change
-$0.00 (-0.00%)
Updated
Nov 11 closing price
Ad is loading...

SLNCF vs SOLTF

Header iconSLNCF vs SOLTF Comparison
Open Charts SLNCF vs SOLTFBanner chart's image
Silence Therapeutics
Price$5.50
Change-$0.00 (-0.00%)
Volume$110
CapitalizationN/A
Nxera Pharma
Price$8.05
Change-$0.00 (-0.00%)
Volume$200
CapitalizationN/A
SLNCF vs SOLTF Comparison Chart
Loading...
View a ticker or compare two or three
VS
SLNCF vs. SOLTF commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SLNCF is a Buy and SOLTF is a Buy.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (SLNCF: $5.50 vs. SOLTF: $8.05)
Brand notoriety: SLNCF and SOLTF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SLNCF: 17% vs. SOLTF: 38%
Market capitalization -- SLNCF: $772.16M vs. SOLTF: $669.82M
SLNCF [@Biotechnology] is valued at $772.16M. SOLTF’s [@Biotechnology] market capitalization is $669.82M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SLNCF’s FA Score shows that 0 FA rating(s) are green whileSOLTF’s FA Score has 0 green FA rating(s).

  • SLNCF’s FA Score: 0 green, 5 red.
  • SOLTF’s FA Score: 0 green, 5 red.
According to our system of comparison, SLNCF is a better buy in the long-term than SOLTF.

Price Growth

SLNCF (@Biotechnology) experienced а -4.84% price change this week, while SOLTF (@Biotechnology) price change was +5.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
SLNCF($772M) has a higher market cap than SOLTF($670M). SLNCF YTD gains are higher at: 266.667 vs. SOLTF (-19.480). SLNCF has higher annual earnings (EBITDA): -47.64M vs. SOLTF (-3.81B). SOLTF has more cash in the bank: 51B vs. SLNCF (150M). SLNCF has less debt than SOLTF: SLNCF (184K) vs SOLTF (71.1B). SOLTF has higher revenues than SLNCF: SOLTF (23.3B) vs SLNCF (17.9M).
SLNCFSOLTFSLNCF / SOLTF
Capitalization772M670M115%
EBITDA-47.64M-3.81B1%
Gain YTD266.667-19.480-1,369%
P/E RatioN/AN/A-
Revenue17.9M23.3B0%
Total Cash150M51B0%
Total Debt184K71.1B0%
FUNDAMENTALS RATINGS
SLNCF vs SOLTF: Fundamental Ratings
SLNCF
SOLTF
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
86
Overvalued
PROFIT vs RISK RATING
1..100
92100
SMR RATING
1..100
9691
PRICE GROWTH RATING
1..100
3679
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLNCF's Valuation (56) in the null industry is in the same range as SOLTF (86). This means that SLNCF’s stock grew similarly to SOLTF’s over the last 12 months.

SLNCF's Profit vs Risk Rating (92) in the null industry is in the same range as SOLTF (100). This means that SLNCF’s stock grew similarly to SOLTF’s over the last 12 months.

SOLTF's SMR Rating (91) in the null industry is in the same range as SLNCF (96). This means that SOLTF’s stock grew similarly to SLNCF’s over the last 12 months.

SLNCF's Price Growth Rating (36) in the null industry is somewhat better than the same rating for SOLTF (79). This means that SLNCF’s stock grew somewhat faster than SOLTF’s over the last 12 months.

SLNCF's P/E Growth Rating (100) in the null industry is in the same range as SOLTF (100). This means that SLNCF’s stock grew similarly to SOLTF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SVPSX88.97-0.67
-0.75%
ProFunds Small Cap Value Svc
RBAIX27.88-0.21
-0.75%
T. Rowe Price Balanced I
PSSJX26.67-0.25
-0.93%
Principal SmallCap S&P 600 Index J
BOPAX28.83-0.49
-1.67%
Sterling Capital Special Opps A
HLHIX29.15-0.68
-2.28%
Virtus KAR Health Sciences Inst

SLNCF and

Correlation & Price change

A.I.dvisor tells us that SLNCF and ENVB have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SLNCF and ENVB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLNCF
1D Price
Change %
SLNCF100%
N/A
ENVB - SLNCF
29%
Poorly correlated
-8.06%
RNXT - SLNCF
24%
Poorly correlated
N/A
QLGN - SLNCF
21%
Poorly correlated
-11.33%
SOLTF - SLNCF
9%
Poorly correlated
N/A
PVCT - SLNCF
8%
Poorly correlated
-0.81%
More

SOLTF and

Correlation & Price change

A.I.dvisor indicates that over the last year, SOLTF has been loosely correlated with BIESF. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if SOLTF jumps, then BIESF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SOLTF
1D Price
Change %
SOLTF100%
N/A
BIESF - SOLTF
35%
Loosely correlated
N/A
BSFAF - SOLTF
29%
Poorly correlated
N/A
BITRF - SOLTF
23%
Poorly correlated
N/A
SPHRF - SOLTF
23%
Poorly correlated
N/A
SLNCF - SOLTF
9%
Poorly correlated
N/A
More